Fig. 7.

p110β kinase activity is required for ERBB2-driven breast cancer cell proliferation. A) Western blot analysis of protein expression in cultured mammary tumors of the two genotypes with the indicated antibodies. B) Proliferation curves, reported as relative increase in the number of cells compared to the initial seeding density, of cultured tumor cells of the two genotypes in the absence or presence of the p110β selective inhibitors TGX-155 (10 μM) and TGX-221 (100 nM). Statistical significance: wild-type cells vs. all other conditions (* P < 0.05, ** P < 0.01); other pairs of datasets: not significant.